BIO
Bio-Rad Laboratories Inc. Class A
$287.84
+$6.42(+2.28%)
52
Overall
60
Value
54
Tech
42
Quality
Market Cap
$7.89B
Volume
218.79K
52W Range
$211.43 - $343.12
Target Price
$308.75
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $2.1B | $2.2B | $2.3B | $2.3B | $2.5B | $2.9B | $2.8B | $2.7B | $2.6B | $2.6B | ||
| Total Revenue | $2.1B | $2.2B | $2.3B | $2.3B | $2.5B | $2.9B | $2.8B | $2.7B | $2.6B | $2.6B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $930.1M | $972.5M | $1.1B | $1.1B | $1.1B | $1.3B | $1.2B | $1.2B | $1.2B | $1.2B | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $1.1B | $-972.5M | $-1.1B | $-1.1B | $1.4B | $1.6B | $1.6B | $1.4B | $1.4B | $1.3B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $1.0B | $1.1B | $1.0B | $1.0B | $1.0B | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | ||
| Research & Development | $205.9M | $250.2M | $199.2M | $202.7M | $226.6M | $260.6M | $256.9M | $247.4M | $295.9M | $275.6M | ||
| Research Expense | $205.9M | $250.2M | $199.2M | $202.7M | $226.6M | $260.6M | $256.9M | $247.4M | $295.9M | $275.6M | ||
| Selling, General & Administrative | $816.7M | $806.8M | $834.8M | $824.6M | $800.3M | $877.1M | $827.8M | $841.7M | $814.0M | $844.3M | ||
| Selling & Marketing Expenses | $816.7M | $806.8M | $834.8M | $824.6M | $800.3M | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $-44.4M | $-43.6M | $-47.4M | -- | -- | $877.1M | $827.8M | $841.7M | $814.0M | $844.3M | ||
| Salaries & Wages | $-19.7M | $-23.4M | $-27.8M | $-35.6M | $-41.6M | $-7.4M | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-142.9M | $-148.7M | $-138.1M | $-40.3M | $-37.1M | $137.6M | $137.3M | $145.9M | $151.6M | -- | ||
| Depreciation & Amortization | $-142.9M | $-148.7M | $-138.1M | $-40.3M | $-37.1M | $137.6M | -- | -- | -- | -- | ||
| Amortization | $-33.5M | $-29.4M | $-27.0M | $-24.1M | $-28.8M | $345.5M | $406.9M | $414.0M | $411.1M | -- | ||
| Other Operating Expenses | $-3.4M | $-34.8M | $-4.6M | $-51.4M | $-45.4M | $-18.1M | -- | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $115.5M | $-2.0B | $-2.1B | $-2.1B | $-2.1B | $500.3M | $482.6M | $337.8M | $269.0M | $47.2M | ||
| EBITDA | $63.5M | $120.8M | $536.6M | $2.2B | $5.1B | $5.6B | $-4.7B | $-800.7M | $-2.3B | $1.0B | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $21.9M | $23.0M | $24.0M | $23.4M | $21.9M | $1.6M | $38.1M | $49.4M | $48.9M | $49.0M | ||
| Intinc | -- | -- | -- | -- | -- | -- | -- | -- | $82.0M | -- | ||
| Net Non-Operating Interest Income/Expense | $-21.9M | $-23.0M | $-24.0M | $-23.4M | $-21.9M | $-1.6M | $-19.9M | $-49.4M | $-48.9M | $-49.0M | ||
| Gain on Sale of Securities | $800.0K | $7.0M | $606.2M | $2.0B | $4.5B | $8.0M | -- | -- | -- | -- | ||
| Other Income/Expense | $-14.8M | $-2.2B | $-2.9B | $-4.4B | $-7.1B | $-5.0B | $-5.2B | $1.1B | $2.6B | $-817.9M | ||
| Other Special Charges | $14.8M | $2.2B | $2.3B | $2.3B | $2.6B | $26.8M | $44.6M | $106.5M | $90.3M | $90.3M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $-12.5M | -- | -- | -- | -- | $-11.2M | -- | -- | -- | -- | ||
| Special Income Charges | $-62.3M | $-11.5M | $-292.5M | -- | $35.3M | $11.2M | $-4.2M | $-27.9M | -- | -- | ||
| Impairment of Capital Assets | $62.3M | $11.5M | $292.5M | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $63.5M | $120.8M | $536.6M | $2.3B | $4.9B | $5.5B | $-4.7B | $-800.7M | $-2.3B | $1.0B | ||
| Pre-Tax Income | $41.6M | $97.8M | $512.7M | $2.3B | $4.9B | $5.4B | $-4.7B | $-850.1M | $-2.3B | $995.5M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $15.6M | $-24.4M | $147.0M | $502.4M | $1.1B | $1.2B | $-1.1B | $-212.8M | $-498.3M | $235.6M | ||
| NET INCOME | ||||||||||||
| Net Income | $26.0M | $122.2M | $365.6M | $1.8B | $3.8B | $4.3B | $-3.6B | $-637.3M | $-1.8B | $759.9M | ||
| Net Income (Continuing Operations) | $26.0M | $122.2M | $365.6M | $1.8B | $3.8B | $4.3B | $-3.6B | $-637.3M | $-1.8B | $759.9M | ||
| Net Income (Discontinued Operations) | $26.0M | $122.2M | $365.6M | $1.8B | $3.8B | $4.3B | $-3.6B | $-637.3M | $-1.8B | $759.9M | ||
| Net Income (Common Stockholders) | $26.0M | $122.2M | $365.6M | $1.8B | $3.8B | $4.3B | $-3.6B | $-637.3M | $-1.8B | $759.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $1.2B | ||
| TOTALS | ||||||||||||
| Total Expenses | $2.0B | $2.0B | $2.1B | $2.1B | $2.1B | $2.4B | $2.3B | $2.3B | $2.3B | $2.4B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $29.4M | $29.7M | $29.8M | $29.8M | $29.8M | $29.8M | $29.8M | $29.2M | $28.2M | $27.3M | ||
| Average Shares Outstanding (Diluted) | $29.6M | $30.0M | $30.2M | $30.2M | $30.2M | $30.2M | $29.8M | $29.2M | $28.2M | $27.3M | ||
| Shares Outstanding | $29.6M | $29.8M | $29.8M | $29.9M | $29.8M | $29.9M | $29.6M | $28.5M | $28.0M | $27.0M | ||
| Basic EPS | $0.96 | $4.12 | $12.25 | $58.93 | $127.86 | $142.33 | $-121.79 | $-21.82 | $-65.36 | $27.87 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $142.33 | $-121.79 | $-21.82 | $-65.36 | $27.87 | ||
| Diluted EPS | $0.95 | $4.07 | $12.1 | $58.27 | $126.2 | $140.56 | $-121.79 | $-21.82 | $-65.36 | $27.85 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $140.56 | $-121.79 | $-21.82 | -- | $27.85 | ||
| OTHER METRICS | ||||||||||||
| Gain On Sale Of Business | $-400.0K | $-1.2M | -- | $-900.0K | $1.3M | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | $-600.0K | $-8.1M | $5.1M | -- | $11.7M | -- | -- | -- | -- | -- | ||
| Non Recurring Operation Expense | $-141.6K | $-141.6K | $-141.6K | -- | $-35.3M | -- | -- | -- | -- | -- | ||
| Other Gand A | $-44.4M | $-43.6M | $-47.4M | -- | -- | $877.1M | $827.8M | $841.7M | $814.0M | $844.3M | ||
| Other Impairment Of Capital Assets | $-46.4M | $-7.0M | $-800.0K | $-5.8M | $-4.6M | $800.0K | -- | -- | -- | $172.8M | ||
| Other Write Off | -- | -- | -- | $-6.6M | $-1.6M | $-1.4M | -- | -- | -- | -- | ||
| Rent And Landing Fees | $-44.4M | $-43.6M | $-47.4M | -- | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $816.7M | $806.8M | $834.8M | $824.6M | $800.3M | -- | -- | -- | -- | -- | ||
| Write Down | -- | -- | $-1.4M | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | $-12.5M | -- | -- | -- | -- | $-11.2M | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BIO | $287.84 | +2.3% | 218.79K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Bio-Rad Laboratories Inc. Class A Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW